Abstract
Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.
| Original language | English |
|---|---|
| Pages (from-to) | 95-97 |
| Number of pages | 3 |
| Journal | OncoTargets and Therapy |
| Volume | 6 |
| DOIs | |
| Publication status | Published - 20 Mar 2013 |
Keywords
- Molecular profiling
- PI3K
- Pancreatic cancer
- Targeted therapy